Novel investigational agents (IAs) aim to exploit new mechanisms and cancer vulnerabilities, expanding our arsenal of anticancer drugs. Recently, highly selective biomarker-directed IAs have allowed advancements in the precision treatment oncogene-driven cancers by decreasing toxicity increasing activity. In phase I drug development, a global problem unknown magnitude is multiplicity similar dr...
